Disclosed herein are processes for the preparation of compounds of formula (I) from one or more bio-derived reactants, and their use as base oils:

(R.sub.1-A).sub.b-(CH.sub.x).sub.a(CHR.sub.2).sub.m(C(R.sub.4R.sub.5)).sub.n(CHR.sub.3).sub.o(CH.sub.y).sub.c-(A-R.sub.1).sub.d(I)

wherein a and c are independently 0 or 1, b and d are independently 1 or 2, x and y are independently 1 or 2, dependent upon the values of a-d, m and o are independently 0 or 1, n is an integer of 0-6, and each A is independently an unsaturated furan ring, a partially saturated furan ring, a saturated furan ring, or (CH.sub.2).sub.4. Also, R.sub.1, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from the group consisting of H and alkyl groups having 1 to 18 carbon atoms, with a proviso that at least one of R.sub.2, R.sub.3, R.sub.4, and R.sub.5 is not hydrogen, and the total carbon content of the compound of formula (I) is in the range of 20-62.

The present invention relates to a method for production of a fuel composition, more specifically a middle distillate fuel composition, and a compositionin particular a co feed composition comprising a furanyl containing oligomerisation composition admixed with one or more material component comprising fatty acids or fatty acid derivatives and the use of such composition.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

Disclosed are compounds, for example, a compound of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

Disclosed are compounds, for example, a compound of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.